📣 VC round data is live. Check it out!
- Public Comps
- Veeva
Veeva Valuation Multiples
Discover Veeva's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like IQVIA, GE HealthCare, Roper Technologies, IDEXX Laboratories and more.
Veeva Overview
About Veeva
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Founded
2007
HQ

Employees
7.3K
Website
Financials (LTM)
EV
$23B
Valuation Multiples
Start free trialVeeva Financials
Veeva reported last 12-month revenue of $3B and EBITDA of $2B.
In the same LTM period, Veeva generated $3B in gross profit, $2B in EBITDA, and $1B in net income.
Revenue (LTM)
Veeva P&L
In the most recent fiscal year, Veeva reported revenue of $3B and EBITDA of $1B.
Veeva is profitable as of last fiscal year, with gross margin of 76%, EBITDA margin of 45%, and net margin of 42%.
Financial data powered by Morningstar, Inc.
Veeva Stock Performance
Veeva has current market cap of $30B, and enterprise value of $23B.
Market Cap Evolution
Veeva's stock price is $182.94.
Veeva share price increased by 4.9% in the last 30 days, and decreased by 36.5% in the last year.
Veeva has an EPS (earnings per share) of $8.29.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23B | $30B | -3.0% | 4.9% | 4.1% | -36.5% | $8.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVeeva Valuation Multiples
Veeva trades at 7.0x EV/Revenue multiple, and 15.5x EV/EBITDA.
EV / Revenue (LTM)
Veeva Financial Valuation Multiples
As of June 3, 2026, Veeva has market cap of $30B and EV of $23B.
Veeva has a P/E ratio of 21.4x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Veeva Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Veeva Margins & Growth Rates
Veeva grew revenue by 13% and EBITDA by 11% in the last fiscal year.
In the most recent fiscal year, Veeva reported gross margin of 76%, EBITDA margin of 45%, and net margin of 42%.
Veeva Margins
Veeva Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Veeva Operational KPIs
Veeva's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Veeva's Rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Veeva's Rule of X is 76% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Veeva Competitors
Veeva competitors include IQVIA, GE HealthCare, Roper Technologies, IDEXX Laboratories, United Imaging, Pro Medicus, ICON plc, Glaukos, M3 Inc. and Waystar.
Most Veeva public comparables operate across Healthcare Software, B2B SaaS, Vertical SaaS and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.7x | 2.6x | 11.6x | 11.4x | |||
| 1.8x | 1.7x | 9.6x | 9.8x | |||
| 5.6x | 5.4x | 13.9x | 13.6x | |||
| 10.3x | 9.9x | 29.4x | 28.0x | |||
| 6.5x | 6.0x | 35.4x | 34.5x | |||
| 77.5x | 64.5x | 100.1x | 71.5x | |||
| 1.6x | 1.7x | 8.8x | 9.3x | |||
| 12.5x | 11.3x | (192.2x) | 1827.7x | |||
This data is available for Pro users. Sign up to see all Veeva competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Veeva
Veeva has acquired 7 companies to date.
Last acquisition by Veeva was on March 9th 2026. Veeva acquired Ostro for $100M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Veeva
| Description | Ostro is a Miami-based health engagement platform founded in 2019. It delivers personalized digital journeys for life sciences brands connecting patients, healthcare providers, and pharma companies. Features include content delivery, adherence tracking, and analytics for medications in oncology, cardiology, and rare diseases. | Veracity Logic is a U.S.-based provider of Interactive Response Technology systems for clinical trials. Formally launched in 2005 after initial release in 2003, its VLIRT platform offers customizable randomization, inventory management, and patient tracking for pharma and biotech sponsors. Veracity Logic delivers international solutions with emphasis on configurability and responsive support. | Learnaboutgmp is a U.K.-based online training platform specializing in Good Manufacturing Practice compliance courses for pharmaceutical, biotech, and medical device sectors. Modules cover sterile processing, quality systems, and FDA regulations with interactive simulations and assessments. Launched in 2010, it serves global organizations through SCORM-compliant content accessible on desktops and mobiles. | Physicians World is a pharmaceuticals business process outsourcing firm headquartered in Hyderabad, India. The company offers services including regulatory compliance support, pharmacovigilance, clinical data management, and medical writing for global pharmaceutical clients. Established to streamline drug development processes, it employs specialized teams handling Phase I through IV trials and post-marketing surveillance. | |
| HQ Country | |||||
| HQ City | Miami, FL | Chapel Hill, NC | Allentown, PA | San Francisco, CA | |
| Deal Date | 9 Mar 2026 | 13 Dec 2021 | 3 Aug 2021 | 7 Nov 2019 | |
| Valuation | $100M | undisclosed | undisclosed | $41M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Veeva acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Veeva
| When was Veeva founded? | Veeva was founded in 2007. |
| Where is Veeva headquartered? | Veeva is headquartered in United States. |
| How many employees does Veeva have? | As of today, Veeva has over 7K employees. |
| Who is the CEO of Veeva? | Veeva's CEO is Peter P. Gassner. |
| Is Veeva publicly listed? | Yes, Veeva is a public company listed on NYSE. |
| What is the stock symbol of Veeva? | Veeva trades under VEEV ticker. |
| When did Veeva go public? | Veeva went public in 2013. |
| Who are competitors of Veeva? | Veeva main competitors include IQVIA, GE HealthCare, Roper Technologies, IDEXX Laboratories, United Imaging, Pro Medicus, ICON plc, Glaukos, M3 Inc., Waystar. |
| What is the current market cap of Veeva? | Veeva's current market cap is $30B. |
| What is the current revenue of Veeva? | Veeva's last 12 months revenue is $3B. |
| What is the current revenue growth of Veeva? | Veeva revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Veeva? | Current revenue multiple of Veeva is 7.0x. |
| What is the current EBITDA of Veeva? | Veeva's last 12 months EBITDA is $2B. |
| What is Veeva's EBITDA margin? | Veeva's last 12 months EBITDA margin is 45%. |
| What is the current EV/EBITDA multiple of Veeva? | Current EBITDA multiple of Veeva is 15.5x. |
| What is the current FCF of Veeva? | Veeva's last 12 months FCF is $1B. |
| What is Veeva's FCF margin? | Veeva's last 12 months FCF margin is 43%. |
| What is the current EV/FCF multiple of Veeva? | Current FCF multiple of Veeva is 16.2x. |
| How many companies Veeva has acquired to date? | As of June 2026, Veeva has acquired 6 companies. |
| What was the largest acquisition by Veeva? | $430M acquisition of Veeva on 26th September 2019 was the largest M&A Veeva has done to date. |
| What companies Veeva acquired? | Veeva acquired Veeva, Ostro, Physicians World, Veracity Logic, Learnaboutgmp, and Selligy. |
| In how many companies Veeva has invested to date? | Veeva hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Veeva
Lists including Veeva
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
